A BLINDED CONTROLLED STUDY OF ALENDRONATE IN CHRONIC SPINAL CORD INJURY

阿仑膦酸钠治疗慢性脊髓损伤的盲对照研究

• 批准号: 7376937
• 负责人: PETER H GORMAN
• 金额: $ 1.04万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376937
• 关键词: BLINDED; CONTROLLED; STUDY; ALENDRONATE; CHRONIC

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Bone, Density is known to be compromised in the Spinal Cord Injured Population. This double-blind, placebo-comtrolled, single center trial will ascertain the ability of a medication called alendronate to increase or maintain the bone density of individuals with spinal cord injury who are at least 18 months past their injury. Participants should be between age 18 and 60 and must rely on a wheelchair for mobility. Participants will be asked over a one-year period to take calcium and Vitamin D supplements each day and to take alendronate (or placebo) once each week. Bone density measurements using an x-ray like device will be done at enrollment and repeated at 6 months and one year. Laboratory measurements will be made every three months over that year, and each measurement will require a visit to the GCRC lab at UMMS. Participants will receive a small stipend to cover their travel and other costs of participati

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。已知脊髓损伤人群的骨密度受损。这项双盲、安慰剂对照、单中心试验将确定一种名为阿仑膦酸钠的药物增加或维持脊髓损伤患者骨密度的能力，这些患者至少在损伤后18个月。参加者年龄在18至60岁之间，必须依靠轮椅行动。参与者将被要求在一年内每天服用钙和维生素D补充剂，每周服用一次阿仑膦酸钠（或安慰剂）。将在入组时使用X射线类器械进行骨密度测量，并在6个月和1年时重复测量。实验室测量将在该年每三个月进行一次，每次测量都需要访问UMMS的GCRC实验室。参加者将获得一小笔津贴，以支付他们的旅费和其他参加费用。